We explore what the joint clinical assessment (JCA) is, its process and what future developments may...
Read morePayer value proposition development and understanding evidence requirements to secure pricing and re...
Read moreOur experts provide an overview of the five key trends that could shape the pricing and market acces...
Read moreAll other aspects of the voluntary scheme remain unchanged.
Read moreThe report looks at four possible scenarios including most notably the creation of a “grande Sécu...
Read moreITC can provide an estimate of the relative treatment effect of two products that have not been comp...
Read moreWe’ve prepared a summary of our key market access blogs and news articles from the second quarter ...
Read moreRemap Consulting has significant expertise in guiding companies through both EUnetHTA / EMA Parallel...
Read moreTo tackle antibiotic resistance, novel antibiotics are being reserved as later-line therapy for more...
Read morePayers are responsible for making choices on which products or services to fund from limited healthc...
Read more